Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Claims

39 · 1 independent · depth 4

39 granted claims

›1.independentAn antisense compound, or a salt form thereof, 12 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B wherein sa…+38

›2.↳ 1The antisense compound of claim 1, wherein said antisense compound is 20 to 30 nucleobases in length.d2+6

›3.↳ 1The antisense compound of claim 1, wherein said antisense compound is 20 nucleobases in length.d2

›4.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises one or more modifications selected from the group consisting of: a modifi…d2

›8.↳ 1The antisense compound of claim 1, wherein the antisense compound is a chimeric oligonucleotide having a plurality of 2⬲-deoxynucleotides flanked on e…d2+4

›14.↳ 1The antisense compound of claim 1, wherein the antisense oligonucleotide is a salt form.d2+1

›18.↳ 1The antisense compound of claim 1, wherein said antisense compound is a gapmer comprising a gap segment comprised of linked 2⬲-deoxynucleotides positi…d2+8

›19.↳ 18The antisense compound of claim 18, wherein said wing segments comprise at least one modified sugar moiety selected from the group consisting of a 2⬲-…d3+2

›22.↳ 18The antisense compound of claim 18, wherein said gap segment is ten 2⬲-deoxynucleotides in length and each of said wing segments is five 2⬲-O-methoxye…d3

›23.↳ 18The antisense compound of claim 18, wherein the antisense oligonucleotide comprises at least one modified nucleobase.d3

›24.↳ 18The antisense compound of claim 18, wherein the modified nucleobase is a 5-methylcytosine.d3

›25.↳ 18The antisense compound of claim 18, wherein the antisense oligonucleotide is a salt form.d3

›26.↳ 18The antisense compound of claim 18, wherein the salt form is a sodium salt form.d3

›27.↳ 1The antisense compound of claim 1, wherein the antisense compound is an antisense oligonucleotide.d2

›28.↳ 1A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier, excipient or diluent.d2+4

›33.↳ 1The antisense compound of claim 1, havingni. a gap segment of ten linked 2⬲-deoxynucleosides,ii. a 5⬲ wing segment of five linked nucleosides, andiii.…d2

›34.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises at least 8 consecutive nucleobases selected from SEQ ID NO:56.d2

›35.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises at least 8 consecutive nucleobases selected from SEQ ID NO:68.d2

›36.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises at least 8 consecutive nucleobases selected from SEQ ID NO:69.d2

›37.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises 20 consecutive nucleobases selected from SEQ ID NO:56.d2

›38.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises 20 consecutive nucleobases selected from SEQ ID NO:68.d2

›39.↳ 1The antisense compound of claim 1, wherein said antisense compound comprises 20 consecutive nucleobases selected from SEQ ID NO:69.d2

Classifications

11 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/70

Section C — Chemistry; metallurgy

C07H21/04
C12Q1/68
C12N5/00
C07H21/02

USPC · US Patent Classification

514/44.A536/24.5536/24.1536/23.1435/377435/375

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

5.6 y

2,028 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Examiner

Sean McGarry

art unit 1635 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 232 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20080242629 A1	2 Oct 2008

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.